![]() We gathered data on adult patients with bronchiectasis (age ≥18) who were prescribed LAMA, LABA, or both between January 2008 and December 2018 at Asan Medical Center, a tertiary referral hospital in Seoul, Korea. This was a retrospective, observational study comparing the lung functions in patients with bronchiectasis before and after long-acting bronchodilator treatment to evaluate the effectiveness of LAMA and LABA. We thus evaluated the effectiveness of LAMA and LABA in improving the lung function of patients with bronchiectasis. Although current practice guidelines suggest using bronchodilators such as long-acting muscarinic antagonists (LAMA) or long-acting beta-agonists (LABA) in bronchiectasis patients with low lung functions, empirical evidences for supporting such guidelines are sparse ( 6). ![]() Poor lung function is a predictor of exacerbation and also an indicator of deterioration in patients with bronchiectasis ( 4, 5). In bronchiectasis, inflammation and chronic bronchial infections cause airway structural changes, and more than 50% of patients have airflow obstructions as a result ( 1). Approximately 18% of patients with bronchiectasis require hospitalization, and the in-hospital all-cause mortality is 2.9% ( 2). Bronchiectasis is a particularly important disease entity in South Korea because its overall prevalence is higher than those in other countries ( 2, 3). Bronchiectasis is a chronic lung disease characterized by cough, sputum, and repeated bronchial infections with permanent bronchial dilatation ( 1).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |